

REMARKS

Reconsideration of this application, as amended, is respectfully requested. By this Amendment, claim 5 is being amended to correct a typographical error, and claims 8-10 and 18 are being amended and new claims 39-41 are being added in view of the restriction requirement. The addition of "new matter" has been scrupulously avoided. Claims 1-22, 36 and 39-41 remain in this case.

In the initial Office Action, the Examiner required restriction between:

Group I comprising claims 1-18, 22 and 36 drawn to a method of treating or preventing graft rejection; and

Group II comprising claims 19-21 drawn to a composition.


In addition, the Examiner required election of a single species of immunosuppression drug and peptide structure for examination on the merits.

In response to the Restriction Requirement contained in the Office Action dated October 8, 2008, Applicant hereby elects Group I comprising claims 1-18, 22 and 36 and elects cyclosporin A as the immunosuppression drug species and Copolymer-1 as the peptide structure species for further examination in the present application. Claims 1, 2, 4-10, 18 and 39-41 read on the elected species.

Upon the allowance of a generic claim, Applicant expressly reserves the right to consideration of claims to additional species which depend from or otherwise require all of the limitations of an allowable generic claim.

If it would advance the prosecution of this application, the Examiner is invited to contact Applicant's representative at the below indicated telephone number.

Respectfully submitted,



Jeff Rothenberg, Reg. No. 26,429
Attorney for Applicant

Dated: Nov. 3, 2008

Heslin Rothenberg Farley & Mesiti P.C.
5 Columbia Circle
Albany, NY 12203
Tel: 518-452-5600
Fax: 518-452-5579
E-mail: jr@hrfmlaw.com